ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COX-2"

  • Abstract Number: 1492 • ACR Convergence 2022

    Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort

    Murat Torgutalp1, valeria Rios-Rodriguez2, Ani Dilbaryan3, Fabian Proft4, Mikhail Protopopov5, Maryna Verba6, Judith Rademacher5, Hildrun Haibel1, Joachim Sieper1, Martin Rudwaleit7 and Denis Poddubnyy4, 1Charité - Universitätsmedizin, Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, 4Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany, 6Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, 7University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

    Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
  • Abstract Number: 1751 • ACR Convergence 2022

    Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

    Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA

    Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
  • Abstract Number: 1831 • ACR Convergence 2022

    Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)

    Judith Boice1, Travis Helm1, Maria Bermudez2, Mark Corrigan1 and Bradford Sippy1, 1Tremeau Pharmaceuticals, Inc, Concord, MA, 2Clinical Pharmacology of Miami, LLC, Miami, FL

    Background/Purpose: TRM-201 (rofecoxib) is a cyclooxygenase-2 (COX-2) selective inhibitor being developed for the treatment of hemophilic arthropathy (HA) and acute migraine. Previously marketed as VIOXX,…
  • Abstract Number: 1860 • ACR Convergence 2022

    Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis

    Nilesh Kodali1, Thomas Vazquez2, DeAnna Diaz3, Josh Dan4, Grant Sprow5, Rohan Dhiman6, Mariko Ogawa-Momohara7, Muhammad Bashir6, Meena Sharma8 and Victoria Werth9, 1New Jersey Medical School, Coppell, TX, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3Philadelphia College of Medicine, Philadelphia, PA, 4Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5Albert Einstein College of Medicine, Philadelphia, PA, 6University of Pennsylvania, Philadelphia, PA, 7Nagoya University Graduate School of Medicine, Nagoya, Japan, 8Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 9University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed…
  • Abstract Number: 0732 • ACR Convergence 2021

    Topical Rofecoxib for OA of the Knee

    Bruce Register1, Nancy Lane2, Lee Simon3, John Newsam4, Edward Kisak4, Jed Pheneger5, John Galvin5, Jeffrey Klein6 and Marc Hochberg7, 1BriOri BioTech, Inc., Newport Beach, CA, 2University of California Davis, Hillsborough, CA, 3SDG LLC, West Newton, MA, 4Tioga Research, Inc, San Diego, CA, 5Inotiv, Boulder, CO, 6Sinclair Research Center, Auxvasse, MO, Canada, 7University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
  • Abstract Number: 1739 • ACR Convergence 2020

    Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption

    Sofia Pazmino1, Annelies Boonen2, Diederik De Cock1, Veerle Stouten1, Delphine Bertrand1, Johan Joly3, Rene Westhovens4 and Patrick Verschueren5, 1KU Leuven, Leuven, Belgium, 2Maastricht University Medical Center, Maastricht, Netherlands, 3University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, 4University Hospitals Leuven, Belgium, Leuven, Belgium, 5University Hospital Leuven, Leuven, Belgium

    Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology